期刊
PHARMACOGENETICS
卷 10, 期 5, 页码 407-413出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00008571-200007000-00004
关键词
androgen metabolism; SNP (single nucleotide polymorphism); pharmacogenetic variation
资金
- NCI NIH HHS [CA68581] Funding Source: Medline
Human prostatic steroid 5 alpha-reductase, encoded by the SRD5A2 gene on chromosome band 2p23, catalyses the irreversible conversion of testosterone to dihydrotestosterone (DHT), the most active androgen in the prostate, with NADPH as its cofactor. This enzyme has never been purified but a number of competitive inhibitors have been developed for this enzyme since increased steroid 5 alpha-reductase activity may cause benign prostatic hypertrophy and prostate cancer. We report here the detailed biochemical and pharmacogenetic dissection of the human enzyme by analysing 10 missense substitutions and three double mutants which are all naturally found in humans. Nine of these 13 mutants reduce activity (measured as V-max) by 20% or more, three increase steroid 5 alpha-reductase by more than 15% and one results in essentially unaltered kinetic properties suggesting that it is a truly neutral ('polymorphic') amino acid substitution. Substantial pharmacogenetic variation among the mutants was also observed when three competitive inhibitors, finasteride, GG745 (dutasteride) and PNU157706, were investigated. Our studies not only define the substrate and cofactor binding sites of human steroid 5 alpha-reductase, but also have significant consequences for the pharmacological usage of steroid 5 alpha-reductase inhibitors in human patients treated for prostatic conditions. Pharmacogenetics 10:407-413 (C) 2000 Lippincott Williams & Wilkins.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据